Trials / Completed
CompletedNCT05406440
A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)
A Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, PK and the Effect of MK-8189 on QTc in Participants With Schizophrenia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the safety and tolerability of multiple ascending doses of MK-8189 in participants with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-8189 | MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg. |
| DRUG | Placebo | MK-8189 dose-matching placebo tablets will be administered orally QD. |
Timeline
- Start date
- 2022-07-12
- Primary completion
- 2023-02-24
- Completion
- 2023-02-24
- First posted
- 2022-06-06
- Last updated
- 2024-07-25
- Results posted
- 2024-07-25
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05406440. Inclusion in this directory is not an endorsement.